Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

The field of adjuvant therapy for surgically resected non-small cell lung cancer (NSCLC) has remained practically unchanged for the last 10–15 years, since the results of several large randomized clinical trials evaluating the benefit of platinum-based chemotherapy after surgery were published (1-4).